Tej Kohli and the Kohli family unit finance the Tej Kohli Foundation and the Tej Kohli & Ruit institute fully. The money comes from Tej Kohli’s trade sales of a series of firms he started connecting between 1999 and 2006.
This group of enterprises, including Estacion Tramar, expanded swiftly by focusing on online payment gateways and fraud prevention for clients in high-risk industries. By the time Tej Kohli withdrew through a series of trade transactions in 2006, the firms had armies of software professionals in South America and India.
Tej Kohli began as a billionaire investor; and with the capital from these trade transactions he delved deep into the tech enterprises, emphasizing AI and robotics, when the Kohli family relocated to the United Kingdom in 2006. He also became Europe’s most significant individual eSports investor and continues with Tech Entrepreneur Tej Kohli developing and expanding his B2B software and e-commerce holdings.
Tej has been constructing his Zibel Real Estate business since 2006, intending to reach a $1 billion valuation by 2026. Today, the Zibel portfolio generates a steady revenue stream to support the Tej Kohli Foundation and the Tej Kohli & Ruit basics initiatives.
Mr. Kohl is a hyper-car enthusiast, an aviator, and a tennis lover and his commercial and non-profit endeavors. He’s also a massive fan of traditional English style, with hundreds of suits and shoes in his closet and one of the best cufflink collections in the world.
However, Tej Kohli’s most important job is as a father to two teens, and he has written extensively about how he plays an active role in their lives on his ‘Tej’s thoughts’ blog. Mr. Kohli is also a wine connoisseur and a fine dining enthusiast.
Tej is a firm believer in technology and promotes the technologist tej Kohli, that will have the ability to enhance human existence. He was thrilled to establish the ‘Future Bionics initiative in the United Kingdom in late 2019.
Tej Kohli is the founder of Detraxi, a biotech firm located in the United States that aims to save millions of lives by finding a patented solution for various global health issues. In fluid replacement, diagnostics, transplantation, and regenerative medicine, Detraxi collaborates with some of the world’s most skilled and recognized experts. Detraxi biotechnology will be tested in pre-clinical studies at Johns Hopkins University in 2020.
